Small vessel disease and glymphatic changes in hospitalized and non-hospitalized COVID-19 patients: A study on peak skeletonised mean diffusivity and DTI-ALPS
Author Block: B. Genç, A. Özçağlayan, M. S. Buruk, L. Incesu, K. Aslan; Samsun/TR
Purpose: COVID-19 has also been associated with the development
of dementia, cortical atrophy, and cognitive impairments such as
brain fog, which are challenging or often impossible to detect
using conventional MRI. Peak width of skeletonized mean diffusivity
(PSMD), a recently developed quantitative marker, has been proposed as
a sensitive biomarker for small vessel disease. The aim of
this study is to investigate changes in PSMD, associated with small
vessel disease, and DTI-ALPS parameters, related to the glymphatic
system, in COVID-19 patients.
Methods or Background: Clinical, demographic data, and MRI images were obtained from
the "neuroCOVID MRI dWIand fMRI with reversal learning" dataset
available on OpenNeuro (https://openneuro.org/datasets/ds005364/versions/1.0.0 . After
denoising and eddy current corrections, DTI-ALPS and PSMD index
measurements were performed similarly to the previous literature. The
values of the hospitalized and non-hospitalized COVID groups were
compared separately with the control group.
Results or Findings: The PSMD index was significantly higher in the hospitalized
COVID-positive group (326 x10⁻⁶ mm²/s) compared to the control group
(298 x10⁻⁶ mm²/s, p=0.028), while there was no significant difference
between the non-hospitalized COVID-positive group (301 x10⁻⁶ mm²/s)
and the control group (p=0.953). no significant differences were
observed in left or right DTI-ALPS values between the hospitalized,
non-hospitalized COVID-positive groups, and the control group.
Conclusion: Our study shows that hospitalized COVID-19
patients exhibit an increase in PSMD index, indicative of small vessel
disease, while no such risk exists in non-hospitalized COVID-19
patients. Additionally, contrary to initial concerns, COVID-19 does
not appear to cause glymphatic dysfunction.
Limitations: The use of the DTI-ALPS method to measure glymphatic function remains controversial. Perivascular spaces account for only 1% of cerebral tissue, making it difficult for this method to differentiate diffusion within perivascular spaces from diffusion along other axes.
Funding for this study: No funding was received for this study.
Has your study been approved by an ethics committee? Not applicable
Ethics committee - additional information: We did not apply for ethics approval as the data utilized in this study were obtained from the OpenNeuro database.